Compare CHRW & ASND Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CHRW | ASND |
|---|---|---|
| Founded | 1905 | 2006 |
| Country | United States | Denmark |
| Employees | N/A | N/A |
| Industry | Oil Refining/Marketing | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 16.4B | 17.1B |
| IPO Year | 1997 | 2014 |
| Metric | CHRW | ASND |
|---|---|---|
| Price | $135.94 | $253.39 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 23 | 21 |
| Target Price | $179.30 | ★ $314.49 |
| AVG Volume (30 Days) | ★ 1.7M | 606.3K |
| Earning Date | 10-28-2026 | 11-12-2026 |
| Dividend Yield | ★ 1.86% | N/A |
| EPS Growth | ★ 25.13 | N/A |
| EPS | ★ 4.45 | N/A |
| Revenue | ★ $14,869,380,000.00 | N/A |
| Revenue This Year | $17.58 | $91.55 |
| Revenue Next Year | $6.66 | $46.52 |
| P/E Ratio | $31.00 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $122.21 | $188.08 |
| 52 Week High | $210.33 | $282.15 |
| Indicator | CHRW | ASND |
|---|---|---|
| Relative Strength Index (RSI) | 48.76 | 48.70 |
| Support Level | $132.49 | $235.71 |
| Resistance Level | $138.31 | $260.91 |
| Average True Range (ATR) | 4.55 | 8.31 |
| MACD | 1.23 | -0.78 |
| Stochastic Oscillator | 64.90 | 15.14 |
C.H. Robinson is a top-tier non-asset-based third-party logistics provider with a significant focus on domestic freight brokerage (about 64% of net revenue), which reflects mostly truck brokerage but also rail intermodal. Additionally, the firm operates a large air and ocean forwarding division (26%), which has grown organically and via tuck-in acquisitions over the years. The remainder of revenue consists of transportation management services and a legacy produce-sourcing operation.
Ascendis Pharma AS is a biopharmaceutical company that applies its TransCon technology platform to make a meaningful difference for patients. The firm's product pipeline includes Endocrinology and Oncology, which includes TransCon PTH, TransCon CNP, and others. It operates in the United States, Europe, and the rest of the world and derives the majority of its revenue from the United States.